Skip to main content
Beijing SL Pharmaceutical Co., Ltd. logo

Beijing SL Pharmaceutical Co., Ltd. — Investor Relations & Filings

Ticker · 002038 ISIN · CNE000001L31 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,472 across all filing types
Latest filing 2012-05-24 Board/Management Inform…
Country CN China
Listing Shenzhen Stock Exchange 002038

About Beijing SL Pharmaceutical Co., Ltd.

https://www.slpharm.com.cn

Beijing SL Pharmaceutical Co., Ltd. specializes in the research, development, manufacturing, and commercialization of pharmaceutical products. The company focuses on several therapeutic areas, including cardiovascular and cerebrovascular diseases, oncology, and infectious diseases. Its product portfolio features a range of chemical drugs and active pharmaceutical ingredients (APIs), with key offerings such as clopidogrel bisulfate and amlodipine besylate. Operating with advanced production facilities that adhere to international Good Manufacturing Practice (GMP) standards, the company emphasizes technological innovation and quality control. The organization serves both domestic and international markets, leveraging its integrated R&D platform to develop generic medications and innovative formulations aimed at improving patient outcomes.

Recent filings

Filing Released Lang Actions
关于推荐公司职工代表监事的公告
Board/Management Information Classification · 95% confidence The document is an announcement from Beijing SL Pharmaceutical Co., Ltd. regarding the recommendation of an employee representative supervisor (监事) to the company's supervisory board. It includes a brief biography of the recommended individual and references company governance structure and legal requirements. There is no financial data, no mention of financial results, no regulatory filings or certifications, and no indication of a meeting or voting results. This is a management or board-related announcement about personnel changes in the supervisory board, which fits the category of Board/Management Information (MANG). The document length is short and focused solely on this personnel announcement, confirming it is not a full report or other type of filing.
2012-05-24 Chinese
2011年度股东大会的法律意见书
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is a legal opinion issued by a law firm regarding the 2011 Annual General Meeting (AGM) of Beijing SL Pharmaceutical Co., Ltd. It details the procedures of convening and holding the AGM, the qualifications of attendees, the agenda items discussed, and the voting results. The document confirms the legality and validity of the AGM process and resolutions passed. It does not contain the actual annual report or financial statements but rather focuses on the legal validation of the AGM and its outcomes. The document length is 3874 characters, which is relatively short and consistent with a legal opinion or meeting-related document rather than a full report. Therefore, this document is best classified as a Declaration of Voting Results & Voting Rights Announcements (DVA), as it reports the official results from the shareholder vote at the AGM.
2012-05-24 Chinese
独立董事对于有关事项的独立意见
Board/Management Information Classification · 95% confidence The document is an independent opinion from the independent directors of Beijing Shuanglu Pharmaceutical Co., Ltd. regarding the appointment of senior management and an entrusted loan by a wholly-owned subsidiary. It references compliance with company law, articles of association, and stock exchange rules. The content is a formal opinion on governance and specific corporate actions, not a full financial report, earnings release, or regulatory filing. It is not a report publication announcement since it contains substantive content and opinions. The document fits best under Board/Management Information (MANG) as it concerns board decisions and management appointments, along with oversight of related party transactions.
2012-05-24 Chinese
关于2011年年度报告的补充公告
Report Publication Announcement Classification · 95% confidence The document is titled as a "补充公告" (supplementary announcement) regarding the 2011 annual report of Beijing SL Pharmaceutical Co., Ltd. It references the previously disclosed full 2011 annual report and summary, and provides additional detailed breakdowns of business segment revenue and cost data to comply with disclosure standards. The document length is short (1103 characters) and it explicitly states it is a supplementary announcement to the annual report, not the full annual report itself. Therefore, this is an announcement related to the annual report publication, not the annual report document itself.
2012-05-17 Chinese
2011年年度报告（更新后）
Annual Report Classification · 100% confidence The document is titled "北京双鹭药业股份有限公司 Beijing SL Pharmaceutical Co.,Ltd. 2011 年年度报告" which translates to "2011 Annual Report". It contains detailed financial data for the year 2011, including accounting data, business data summaries, shareholder information, board and management details, governance structure, financial statements, and auditor's report. The document length is about 15,000 characters, indicating a full report rather than a brief announcement. The presence of audited financial statements and comprehensive company information confirms this is the official yearly report covering company activity and full financial performance for the fiscal year 2011. Therefore, the document fits the definition of an Annual Report (10-K). FY 2011
2012-05-17 Chinese
独立董事马清钧2011年度述职报告
Board/Management Information Classification · 95% confidence The document is a detailed annual report by an independent director of Beijing Shuanglu Pharmaceutical Co., Ltd. for the year 2011. It includes comprehensive descriptions of the director's duties, attendance at board and shareholder meetings, independent opinions on audit firm appointments, related party transactions, internal control evaluations, investment decisions, and other governance matters throughout the year. The content is focused on the director's oversight and opinions on the company's governance and financial matters for the full fiscal year 2011. This type of document is characteristic of a Management Report or a Director's Report on corporate governance and oversight activities for the year, which aligns with the category of Board/Management Information (MANG). It is not a full Annual Report (10-K) as it does not contain full financial statements or comprehensive company activity reports, nor is it an Audit Report (AR) or other categories. The document length and detail confirm it is not a brief announcement or certification but a substantive report by a board member.
2012-04-21 Chinese

Browse filings by year

23 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.